ATRA
Atara Biotherapeutics Inc

3,381
Mkt Cap
$99.21M
Volume
43,930.00
52W High
$18.71
52W Low
$5.01
PE Ratio
6.28
ATRA Fundamentals
Price
$15.75
Prev Close
$13.39
Open
$13.19
50D MA
$13.65
Beta
2.28
Avg. Volume
53,334.35
EPS (Annual)
-$11.41
P/B
-2.71
Rev/Employee
$842,745.10
Loading...
Loading...
News
all
press releases
Atara Biotherapeutics (NASDAQ:ATRA) Issues Quarterly Earnings Results, Beats Estimates By $0.51 EPS
Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.32) EPS for the quarter, topping analysts...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...
Business Wire·3d ago
News Placeholder
Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -6.67% and -41.25%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains?
Atara Biotherapeutics (ATRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·8d ago
News Placeholder
Pacira (PCRX) Tops Q3 Earnings Estimates
Pacira (PCRX) delivered earnings and revenue surprises of +7.69% and -1.60%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9d ago
News Placeholder
Adma Biologics (ADMA) Q3 Earnings Match Estimates
Adma Biologics (ADMA) delivered earnings and revenue surprises of 0.00% and +3.17%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
Atara Biotherapeutics (ATRA) Soars 10.0%: Is Further Upside Left in the Stock?
Atara Biotherapeutics (ATRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·2mo ago
News Placeholder
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Zacks·6mo ago
News Placeholder
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
Zacks·6mo ago
News Placeholder
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws Wolf Haldenstein Adler Freeman & Herz LLP...
PR Newswire·9mo ago

Latest ATRA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.